Evaluation of the role of local therapy in patients with cN1M0 prostate cancer: A population-based study from the SEER database

Objective To investigate the prognostic value of local therapy (LT) in cN1M0 prostate cancer (PCa). Methods Patients diagnosed with cN1M0 PCa were extracted from the surveillance, epidemiology, and end results (SEER) database. Kaplan-Meier (KM) curve was used to compare the survival outcomes between patients treated with and without LT. Further, among patients receiving LT, KM analysis was also applied to investigate the survival differences in patients with radical prostatectomy (RP) and radiation therapy (RT). Propensity score matching (PSM) analysis was performed to balance the basic characteristics of patients in each group and make it comparable when exploring the survival impact of different treatment types. Finally, uni- and multivariable Cox proportional-hazards models were utilized to identify independent prognostic factors associated with overall survival (OS) and cancer-specific survival (CSS) in this population. Results Patients treated with LT had significantly better OS (P<0.0001) and CSS (P<0.0001) than those without LT, as well as in most subgroups, except for non-White patients, or those with ISUP grade group 1 or T3 stage. Notably, patients receiving RP also had significantly better OS (P=0.00012) and CSS (P=0.0045) than those treated with RT alone, especially in those aged ≥75 years old, prostate-specific antigen (PSA) 10-20 ng/mL, ISUP grade 1-3 or non-white patients. Finally, clinical T stage, ISUP grade group and the administration of LT were identified to be independent prognostic factors for OS and CSS among cN1M0 PCa patients. Conclusion The cN1M0 PCa patients treated with LT were associated with significantly better survival. Among patients receiving LT, the combination of RP and PLND could lead to a better prognosis compared to RT alone in most subgroups. An individualized treatment strategy is warranted to be developed after weighing the benefits and risks of treatment.

[1]  V. Khoo,et al.  Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. , 2022, JAMA oncology.

[2]  F. Saad,et al.  Survival after radical prostatectomy versus radiation therapy in clinical node‐positive prostate cancer , 2022, The Prostate.

[3]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[4]  K. Bevans,et al.  Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. , 2021, The Lancet. Oncology.

[5]  M. Cooperberg,et al.  Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. , 2021, JAMA oncology.

[6]  Josephine M. E. Gibson,et al.  Non-medical prescribing in primary care in the United Kingdom: an overview of the current literature , 2021, Journal of Prescribing Practice.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  U. Nagele,et al.  Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. , 2021, European urology oncology.

[9]  A. Jha,et al.  Changes in Racial Disparities in Mortality After Cancer Surgery in the US, 2007-2016 , 2020, JAMA network open.

[10]  H. Weir,et al.  Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.

[11]  Y. Shioyama,et al.  The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation? , 2020, Urologic oncology.

[12]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[13]  Shailesh Singh,et al.  Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer , 2019, Cancers.

[14]  H. G. van der Poel,et al.  Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature , 2019, BJU international.

[15]  E. Antonarakis,et al.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.

[16]  Ronald C. Chen,et al.  A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. , 2019, European urology oncology.

[17]  J. Barentsz,et al.  The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. , 2019, European urology.

[18]  A. Amini,et al.  Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging? , 2019, European urology.

[19]  James D. Murphy,et al.  Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. , 2019, European urology oncology.

[20]  P. Meltzer,et al.  Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations , 2018, Journal of Immunotherapy for Cancer.

[21]  Raj Persad,et al.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.

[22]  James D. Murphy,et al.  Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[23]  U. Haberkorn,et al.  68Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature , 2018, Clinical physiology and functional imaging.

[24]  H. Weir,et al.  Liver cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[25]  C. B. Steele,et al.  Prostate cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.

[26]  A. Kural,et al.  The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  J. McKenney,et al.  Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[28]  M. Menon,et al.  Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. , 2017, European urology.

[29]  H. Brenner,et al.  Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions? , 2017, BJU international.

[30]  P. Stricker,et al.  Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer , 2017, BJU international.

[31]  H. Heinzer,et al.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.

[32]  S. Hollinghurst,et al.  Systematic review of the published literature , 2015 .

[33]  A. Jemal,et al.  Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. , 2015, Journal of the National Cancer Institute.

[34]  R. Kumar,et al.  Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. , 2015, Clinical nuclear medicine.

[35]  E. Crawford,et al.  The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. , 2014, International journal of radiation oncology, biology, physics.

[36]  J. Tward,et al.  Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. , 2013, Practical radiation oncology.

[37]  A. Heidenreich,et al.  Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. , 2007, European urology.

[38]  P. Malone,et al.  Prostate , 1995 .

[39]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[40]  A. Stenzl,et al.  Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. , 1990, The Journal of urology.